ConductScience.org, home
Papers
API referenceFor AI assistants

Paper · 41369841

Breast Cancer Progression by the FGF/FGFR Axis: A Metabolic Perspective.

Tuokkola JE and 1 other. J Mammary Gland Biol Neoplasia, 2025. Cited by 3 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Breast Cancer Progression by the FGF/FGFR Axis: A Metabolic Perspective. Papers, record 41369841. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41369841

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Breast Cancer Progression by the FGF/FGFR Axis: A Metabolic Perspective.
PubMed
Journal
J Mammary Gland Biol Neoplasia
PubMed
Year
2025
PubMed
Publication types
Journal Article, Review, Research Support, N.I.H., Extramural
PubMed
Citations, by iCite
3
iCite
Revised in PubMed
2026-07-12
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Tuokkola JEJennifer E
2Schwertfeger KLKathryn L

Source PubMed

Topics9

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Breast NeoplasmsMajor topic
Fibroblast Growth FactorsMajor topic
Receptors, Fibroblast Growth FactorMajor topic
Humans
Female
Signal Transduction
Disease Progression
Animals
Lipid Metabolism

Source PubMed

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
R01 CA215052NCI NIH HHSUnited StatesR01CA215052PubMed and NIHNIH RePORTER
R01 HD106929NICHD NIH HHSUnited StatesR01HD106929PubMed and NIHNIH RePORTER

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References131

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
135,020,204Cancer statistics, 2022.CA Cancer J Clin2022https://conductscience.org/library/papers/35020204PubMed
223,029,290Fibroblast growth factor receptor 1 activation in mammary tumor cells promotes macrophage recruitment in a CX3CL1-dependent manner.PLoS One2012https://conductscience.org/library/papers/23029290PubMed
311,276,432Fibroblast growth factors.Genome Biol2001https://conductscience.org/library/papers/11276432PubMed
529,763,898FGFR4 Links Glucose Metabolism and Chemotherapy Resistance in Breast Cancer.Cell Physiol Biochem2018https://conductscience.org/library/papers/29763898PubMed
635,733,921Tumor Microenvironment: Lactic Acid Promotes Tumor Development.J Immunol Res2022https://conductscience.org/library/papers/35733921PubMed
734,907,199Paracrine FGFs target skeletal muscle to exert potent anti-hyperglycemic effects.Nat Commun2021https://conductscience.org/library/papers/34907199PubMed
817,623,664Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21.J Biol Chem2007https://conductscience.org/library/papers/17623664PubMed
915,475,116Evolution of the Fgf and Fgfr gene families.Trends Genet2004https://conductscience.org/library/papers/15475116PubMed
1038,537,635Tumor-secreted FGF21 acts as an immune suppressor by rewiring cholesterol metabolism of CD8+T cells.Cell Metab2024https://conductscience.org/library/papers/38537635PubMed
1117,372,235Statin use and breast cancer risk in a large population-based setting.Cancer Epidemiol Biomarkers Prev2007https://conductscience.org/library/papers/17372235PubMed

1 to 10 of 131

See all 131 references

Cited by3

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.

PMIDTitleJournalYearIn PapersSource
42,713,141Fibroblast growth factor receptor 1 status discordance between primary breast tumours and lymph node metastases is associated with peripheral blood circulating tumour cell burden.Contemp Oncol (Pozn)2026https://conductscience.org/library/papers/42713141PubMed
42,429,045FGFR1 signaling in rheumatoid arthritis: Mechanisms of bone destruction and therapeutic targeting (Review).Int J Mol Med2026https://conductscience.org/library/papers/42429045PubMed
42,278,446Breast Cancer and Metabolic Dysfunction-Associated Steatotic Liver Disease.Int J Mol Sci2026https://conductscience.org/library/papers/42278446PubMed

Genes0

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

None in this release.

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41369841

GET https://conductscience.org/api/papers/v1/41369841/references?page=2

API referenceFor AI assistants